Drug intelligence / Profile preview

NAL9403

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Drug Delivery Systems
Administration: Intravenous

Overview

NAL9403 is an investigational **intravenous parenteral nutrition** product from NAL Pharma. The sponsor describes it as a multi-component formulation containing omega-3, fat, 16 amino acids, and glucose, intended to provide nutritional substrates intravenously when parenteral nutrition is required. NAL Pharma lists the product under a proposed US ANDA filing. ([nalpharma.com](https://nalpharma.com/licensing.php))

Beyond the preview

Go deeper on NAL9403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL9403.

Explore the full profile